A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Insmed Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 182,300 shares of INSM stock, worth $13.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
182,300
Previous 76,900 137.06%
Holding current value
$13.7 Million
Previous $2.09 Million 485.52%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$22.0 - $69.71 $2.81 Million - $8.91 Million
-127,817 Reduced 13.78%
799,746 $53.6 Million
Q1 2024

May 15, 2024

SELL
$25.72 - $29.94 $3.05 Million - $3.55 Million
-118,651 Reduced 11.34%
927,563 $25.2 Million
Q4 2023

Feb 14, 2024

BUY
$23.42 - $31.74 $10.9 Million - $14.8 Million
466,832 Added 80.57%
1,046,214 $32.4 Million
Q3 2023

Nov 14, 2023

BUY
$19.86 - $26.93 $3.95 Million - $5.36 Million
199,090 Added 52.35%
579,382 $14.6 Million
Q2 2023

Aug 14, 2023

SELL
$16.44 - $21.1 $10.4 Million - $13.3 Million
-631,910 Reduced 62.43%
380,292 $8.02 Million
Q1 2023

May 15, 2023

BUY
$16.26 - $21.73 $7.91 Million - $10.6 Million
486,609 Added 92.58%
1,012,202 $17.3 Million
Q4 2022

Feb 14, 2023

BUY
$16.98 - $23.15 $2.68 Million - $3.65 Million
157,778 Added 42.9%
525,593 $10.5 Million
Q3 2022

Nov 14, 2022

BUY
$20.88 - $28.21 $2.19 Million - $2.96 Million
105,015 Added 39.96%
367,815 $7.92 Million
Q2 2022

Aug 15, 2022

BUY
$17.07 - $25.71 $1.85 Million - $2.79 Million
108,512 Added 70.33%
262,800 $5.18 Million
Q1 2022

May 16, 2022

BUY
$20.42 - $28.13 $2.92 Million - $4.02 Million
142,907 Added 1255.66%
154,288 $3.63 Million
Q4 2021

Feb 14, 2022

SELL
$25.89 - $33.45 $17.6 Million - $22.7 Million
-679,383 Reduced 98.35%
11,381 $310,000
Q2 2021

Aug 16, 2021

BUY
$24.17 - $36.01 $10.7 Million - $15.9 Million
440,661 Added 176.19%
690,764 $19.7 Million
Q1 2021

May 17, 2021

SELL
$32.28 - $44.3 $30.1 Million - $41.4 Million
-933,496 Reduced 78.87%
250,103 $8.52 Million
Q4 2020

Feb 16, 2021

SELL
$31.45 - $40.54 $28.2 Million - $36.3 Million
-896,175 Reduced 43.09%
1,183,599 $39.4 Million
Q3 2020

Nov 16, 2020

SELL
$26.0 - $34.5 $5.58 Million - $7.4 Million
-214,536 Reduced 9.35%
2,079,774 $66.8 Million
Q2 2020

Aug 14, 2020

SELL
$14.11 - $29.42 $12.5 Million - $26 Million
-884,031 Reduced 27.81%
2,294,310 $63.2 Million
Q1 2020

May 15, 2020

BUY
$13.63 - $33.98 $7.53 Million - $18.8 Million
552,566 Added 21.04%
3,178,341 $50.9 Million
Q4 2019

Feb 14, 2020

SELL
$16.12 - $24.98 $7.05 Million - $10.9 Million
-437,247 Reduced 14.28%
2,625,775 $62.7 Million
Q3 2019

Nov 14, 2019

BUY
$15.49 - $25.78 $11.5 Million - $19.1 Million
740,908 Added 31.91%
3,063,022 $54 Million
Q2 2019

Aug 14, 2019

BUY
$23.0 - $32.19 $27.1 Million - $37.9 Million
1,176,356 Added 102.67%
2,322,114 $59.4 Million
Q1 2019

May 15, 2019

BUY
$13.91 - $31.15 $1.08 Million - $2.42 Million
77,755 Added 7.28%
1,145,758 $0
Q4 2018

Feb 14, 2019

BUY
$11.6 - $18.7 $10.8 Million - $17.4 Million
930,003 Added 673.92%
1,068,003 $14 Million
Q3 2018

Nov 13, 2018

SELL
$18.95 - $28.08 $1.6 Million - $2.37 Million
-84,388 Reduced 37.95%
138,000 $0
Q2 2018

Aug 10, 2018

SELL
$20.0 - $29.72 $3.69 Million - $5.48 Million
-184,299 Reduced 45.32%
222,388 $0
Q3 2017

Nov 09, 2017

BUY
$11.61 - $31.21 $4.72 Million - $12.7 Million
406,687
406,687 $12.7 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $10.2B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.